Platelet Arachidonic Acid Metabolism and Eicosanoid Receptors

Advances in Molecular and Cell Biology

Volumn 18, Issue C, 1997, Pages 145-177

  Allan, Claire J ^a   Halushka, Perry V ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0004950563     PISSN: 15692558     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1569-2558(08)60414-2     Document Type: Article

References (193)

1. Anderson N.H., Imamoto S., Subramanian N., Picker D.H., Ladner D.W., De B., Tynan S.S., Eggerman T.C., Harker L.A., Robertson R.P., Oien H.G., and Rao C.V. Molecular basis for prostaglandin potency. III. Tests of the "hairpin conformation" in biorecognition phenomena. Prostaglandins 22 (1981) 841-856
2. 2. Prostaglandins Med 6 (1981) 345-357
3. Aristoff P.A., Harrison A.W., Aiken J.W., Gorman R.R., and Pike J.E. Synthesis and structure-activity relationships of novel stable prostacyclin analogues. In: Samuelsson B., Paoletti R., and Ramwell P.W. (Eds). Advances in Prostaglandin Thromboxane and Leukotriene Research (1983), Raven Press, New York 267-274
4. Aristoff P.A., Johnson P.D., and Harrison A.W. Synthesis of 9-substituted carbacyclin analogues. J. Org. Chem. 48 (1983) 5341-5348
5. 2α is not a thromboxane receptor antagonist on human platelets. Br. J. Pharmacol. 80 (1983) 603
6. Armstrong R.A., Jones R.L., and Wilson N.H. Ligand binding to thromboxane receptors on human platelets: Correlation with biological activity. Br. J. Pharmacol. 79 (1983) 953-964
7. Armstrong R.A., Jones R.L., Peesapati V., Will S.G., and Wilson N.H. Competitive antagonism at thromboxane receptors in human platelets. Br. J. Pharmacol. 84 (1985) 595-607
8. Avdonin P.V., Svitina-Vlitini I.V., Leytin V.L., and Tkachuk V.A. Interaction of stable prostaglandin endoperoxide analogs U46619 and U44069 with human platelet membranes: coupling of receptors with high-affinity GTPase and adenylate cyclase. Thromb. Res. 40 (1985) 101-112
9. 2 receptor-stimulated phosphoinositide hydrolysis in isolated platelet membranes: Involvement of phosphoinositide-specific phospholipase C-ß and GTP-binding Gq. Biochem. J. 291 (1993) 235-240
10. Bertele V., Cerletti C., Schieppati A., DiMinno G., and de Gaetano G. Inhibition of thromboxane synthesis does not necessarily prevent platelet aggregation. Lancet 1 (1981) 1057-1058
11. 2. Nature 315 (1985) 511-513
12. Bonne C., Martin B., and Regnault F. The cyclic AMP-lowering effect of the stable endoperoxide analog U46619 in human platelets. Thromb. Res. 20 (1980) 701-704
13. 2 in human platelets. Thromb. Res. 21 (1981) 13-22
14. Brass L.F. G protein regulators of platelet activation. In: Jamieson G.A. (Ed). Platelet Membrane Receptors: Molecular Biology, Immunology, Biochemistry and Pathology (1988), Alan R. Liss Inc., New York 441-492
15. Bundy G.L., Morton P.R., Peterson D.E., Nishizawa E.E., and Miller W.L. Synthesis and platelet aggregation inhibiting activity of prostaglandin D analogues. J. Med. Chem. 26 (1983) 790-799
16. Coleman R.A., Humphrey P.P.A., Kennedy I., and Lumley P. Prostanoid receptors; the development of a working classification. Trends Pharmacol. Sci. 5 (1984) 303-306
17. 2 receptors in platelets with myeloproliferative disorders. J. Clin. Invest. 64 (1979) 586-590
18. 2 and analogs on platelet aggregation and smooth muscle contraction. J. Pharmacol. Exp. Ther. 206 (1978) 132-138
19. 2 receptor subtypes. J. Clin. Invest. 84 (1989) 1883-1891
20. 2 receptors in patients with acute myocardial infarction. Circulation 81 (1990) 212-218
21. Dusting G.J., Moncada S., and Vane J.R. Prostacyclin: Its biosynthesis, actions and clinical potential. In: Oates J.A. (Ed). Prostaglandins and the Cardiovascular System: Advances in Prostaglandin, Thromboxane and Leukotriene Research (1982), Raven Press, New York 50-106
22. Egan R.W., Tischler A.N., Baptista E.M., Ham E.A., Soderman D.D., and Gale P.H. In: Samuelsson B., Paoletti R., and Ramwell P. (Eds). Advances in Prostaglandin, Thromboxane and Leukotriene Research (1983), Raven Press, New York 151-157
23. Eglen R.M., and Whiting R.L. The action of prostanoid receptor agonists and antagonists on smooth muscle and platelets. Br. J. Pharmacol. 94 (1988) 591-601
24. 2. Science 193 (1976) 1135-1137
25. Feinstein M.B. Platelets, macrophages and neutrophils. In: Michell R.H., Drummond A.H., and Downes C.P. (Eds). Inositol Lipids in Cell Signalling (1989), Academic Press, London 247-281
26. Fitzgerald D.J., Roy L., Catella F., and Fitzgerald G.A. Platelet activation in unstable coronary disease. N. Engl. J. Med. 315 (1986) 983-988
27. Fletcher B.S., Kujubu D.A., Perrin D.M., and Herschman H.R. Structure of the mitogen-inducible TIS-10 gene and demonstration that the TIS-10 encoded protein is a functional prostaglandin G/H synthase. J. Biol. Chem. 267 (1992) 4338-4344
28. Flohé L., Böhlke H., Frankus E., Kimm S.M.A., Lintz W., Loschen G., Michel G., Müller B., Schneider J., Seipp U., Vollenberg W., and Wilsmann K. Designing prostacyclin analogues. Arzneim. Forsch. 33 (1983) 1240-1248
29. Fried J., and Barton J. Synthesis of 13, 14-dehydroprostacyclin methyl ester: a potent inhibitor of platelet aggregation. Proc. Natl. Acad. Sci. USA 74 (1977) 2199-2203
30. Funk C.D., Funk L.B., Kennedy M.E., Pong A.S., and Fitzgerald G.A. Human platelet/erythroleukemia cell prostaglandin G/H synthase: cDNA cloning, expression and gene chromosomal location. FASEB J. 5 (1991) 2304-2312
31. 4 hydrolase. Proc. Natl. Acad. Sci. USA 84 (1987) 6677-6681
32. Gorman R.R., Bundy G.L., Peterson D.C., Sun F.F., Miller O.J., and Fitzpatrick F.A. Inhibition of human platelet thromboxane synthase by 9,11-aza-prosta-5,13-dienoic acid. Proc. Natl. Acad. Sci. USA 74 (1977) 4007-4011
33. Grimm L.J., Knapp D.R., Senator D., and Halushka P.V. Inhibition of platelet thromboxane synthesis by 7-(I-imidazolyl)heptanoic acid; dissociation from inhibition of aggregation. Thromb. Res. 24 (1981) 307-317
34. 3]iloprost, for studying prostacyclin-binding sites on human platelets and neuronal hybrid cells. Biosci. Rep. 4 (1984) 491-498
35. 125I]-labelled ligand. Biochem. Pharmacol. 34 (1985) 1165-1170
36. 2 receptor antagonist to guinea-pig platelets. Eur. J. Pharmacol. 131 (1986) 49-54
37. 2 receptors. Fed. Proc. 46 (1987) 149-153
38. Halushka P.V., Mais D.E., Mayeux P.R., and Morinelli T. Prostaglandin, thromboxane and leukotriene receptors. Annu. Rev. Pharmacol. Toxicol. 29 (1989) 213-239
39. 2 receptors: A growing family of receptor subtypes. In: Bailey J.M. (Ed). Prostaglandins, Leukotrienes, Lipoxins and PAF (1991), Plenum Press, New York 199-210
40. Hamberg M., and Samuelsson B. Prostaglandin endoperoxides Novel transformations of arachidonic acid in human platelets. Proc. Natl. Acad. Sci. USA 71 (1974) 3400-3404
41. Hamberg M., Svensson J., and Samuelsson B. Prostaglandin endoperoxides: A new concept concerning the mode of action and release of prostaglandins. Proc. Natl. Acad. Sci. USA 71 (1974) 3824-3828
42. Hamberg M., Svensson J., Wakabayashi T., and Samuelsson B. Isolation and structure of two prostaglandin endoperoxides that cause platelet aggregation. Proc. Natl. Acad. Sci. USA 71 (1974) 345-349
43. Hamberg M., Svensson J., and Samuelsson B. Thromboxanes: A new group of biologically active compounds derived from prostaglandin endoperoxides. Proc. Natl. Acad. Sci. 72 (1975) 2994-2998
44. 2 interacts at thromboxane receptor sites on guinea pig platelets. Br. J. Pharmacol. 88 (1986) 931-936
45. Hamm C.W., Lorenz R.L., Bleifeld W., Kupper W., Wober W., and Weber P.C. Biochemical evidence of platelet activation in patients with persistent unstable angina. J. Am. Coll. Cardiol. 10 (1987) 988-1004
46. Hammarström S., and Falardeau P. Resolution of prostaglandin endoperoxide synthase and thromboxane synthase of human platelets. Proc. Natl. Acad. Sci. USA 74 (1977) 3691-3695
47. 4 in rats and humans. Adv. Prostaglandin Thromboxane Leukotriene Res. 15 (1985) 185-188
48. 2 receptor antagonist in platelets. Thromb. Res. 50 (1988) 365-376
49. 2 receptor antagonist, in the human platelet and isolated smooth muscle. Eur. J. Pharmacol. 103 (1984) 9-18
50. Haslam R.J. Signal transduction in platelet activation. In: Verstraete M., Vermylen J., Lijnen R., and Arnout J. (Eds). Thrombosis and Hemostasis (1987), Leuven University Press, Leuven, The Netherlands 147-174
51. Haslam R.J., Davidson M.M.L., and Desjardins J.V. Inhibition of adenylate cyclase by adenosine analogues in preparations of broken and intact platelets. Biochem. J. 176 (1978) 83-95
52. Haurand M., and Ullrich V. Characterization of thromboxane synthase from human platelets as a cytochrome P-450 enzyme. J. Biol. Chem. 260 (1985) 15057-15059
53. 2 receptors in human platelets. J. Pharmacol. Exp. Ther. 245 (1988) 786-792
54. 125I]-p-OH-SQ 28,668 in human platelet membranes. Pharmacologist 27 (1985) 241
55. 2 receptor. Nature 349 (1991) 617-620
56. Hirsh P.D., Hillis L.D., Campbell W.B., Firth B.G., and Willerson J.T. Release of prostaglandins and thromboxane into the coronary circulation in patients with ischemic heart disease. N. Engl. J. Med. 304 (1981) 685-691
57. 2 production. Biochem. Pharmacol. 31 (1982) 1158-1160
58. Huang E.M., and Detwiler T.C. Stimulus-response coupling mechanisms. In: Phillips D.R., and Schuman M.A. (Eds). Biochemistry of Platelets (1986), Academic Press Inc., Orlando, FL 1-68
59. 2 antagonist 13-azaprostanoic acid to human platelet membranes. Biochim. Biophys. Acta 728 (1983) 171-178
60. 2-induced human platelet aggregation. Prostaglandins 24 (1982) 195-206
61. Iizuka K., Akahane K., Momose D., and Nakazawa M. Highly selective inhibitors of thromboxane synthase. 1. Imidazole derivatives. J. Med. Chem. 24 (1981) 1139-1148
62. 2 receptor. Circ. Res. 62 (1988) 494-505
63. Johnson R.A., Lincoln F.H., Smith H.W., Ayer D.E., Nidy E.G., Thompson J.L., Axen U., Aiken J.W., Gorman R.R., Nishizawa E.E., and Honohan T. Biological effects of stable prostacyclin analogues. In: Vane J.R., and Bergstrom S. (Eds). Prostacyclin (1979), Raven Press, New York 17-29
64. Jones R.L., Maclntyre D.E., Pollack W.K., Shaw A.M., and Wilson N.H. An extreme of thromboxane-like activity. Br. J. Pharmacol. 84 (1985) 148
65. 17. In: Roberts S.M., and Scheinmann F. (Eds). Chemistry, Biochemistry and Pharmacological Actions of Prostanoids (1979), Pergamon Press, Oxford 210-220
66. Jones R.L., Wilson N.H., and Armstrong R.A. Characterization of thromboxane receptors in human platelets. Adv. Exp. Med. Biol. 192 (1985) 67-81
67. Jones R.L., Wilson N.H., Armstrong R.A., and Tymkewycz P.M. Developments in the characterization of prostaglandin endoperoxide/thromboxane receptors. In: Lagarde M. (Ed). Biology of Icosanoids 152nd (1987), Colloque Inserm, INSERM, Paris, France 335-344
68. 1 induced activation of adenylate cyclase in human blood platelet membranes. Biochim. Biophys. Acta 972 (1988) 45-51
69. 1 binding to human blood platelet membrane by insulin and the activation of adenylate cyclase. J. Biol. Chem. 265 (1990) 4976-4981
70. 1/prostacyclin receptor activity of platelets in acute ischemic heart disease. Circ. Res. 66 (1990) 932-940
71. 2 receptor activity of patients in acute ischemic heart disease. Circ. Res. 68 (1991) 245-254
72. Katsura M., Miyamoto T., Hamanaka N., Kondo K., Terada T., Ohgaki Y., Kawasaki A., and Tsuboshima H. In vitro and in vivo effects of new powerful thromboxane antagonists (3-alkylamine pinane derivatives). Adv. Prostaglandin Thromboxane Leukotriene Res. 11 (1983) 351-357
73. 2 receptor antagonists (12-APA, BM13.177, ONO3508 and SQ29548). Thromb. Res. 41 (1986) 471-481
74. 2 analogue in human platelets. Biochem. Biophys. Res. Commun. 117 (1983) 663-669
75. Kawasaki A., Ishii K., Wakitani K., and Tsuboshima M. Comparison of the activities of prostacyclin and its stable analogues on the platelet aggregation and cardiovascular systems. Adv. Prostaglandin Thromboxane Res. 6 (1980) 331-336
76. Keery R.J., and Lumley P. AH 6809, a selective antagonist at the human platelet DP-receptor?. Br. J. Pharmacol. 85 (1985) 286
77. Keery R.J., and Lumley P. AH 6809, a prostaglandin DP-receptor blocking drug on human platelets. Br. J. Pharmacol. 94 (1988) 745-754
78. Kujubu D.A., and Herschman H.R. Dexamethasone inhibits mitogen induction of the TIS10 prostaglandin synthase/cyclooxygenase gene. J. Biol. Chem. 267 (1992) 7991-7994
79. Kulmacz R.J. Biosynthesis of Prostaglandins. In: Willis A.L. (Ed). CRC Handbook of Eicosanoids: Prostaglandins and other Related Lipids (1987), CRC Press, Boca Raton, FL 163-174
80. Lands W.E.M., Lee R., and Smith W. Factors regulating the biosynthesis of various prostaglandins. Ann. N. Y. Acad. Sci. 180 (1971) 107-122
81. Le Breton G.C., Venton D.L., Enke S.E., and Halushka P.V. 13-Azaprostanoic acid: A specific antagonist of the human blood platelet thromboxane/endoperoxide receptor. Proc. Natl. Acad. Sci. USA 76 (1979) 4097-4101
82. LeDuc L.E., Wyche A.A., Sprecher H., Sankarappe S.K., and Needleman P. Analogues of arachidonic acid used to evaluate structural determinants of prostaglandin receptor and enzyme specificities. Mol. Pharmacol. 19 (1981) 242-247
83. 2. Proc. Natl. Acad. Sci. USA 77 (1980) 1706-1710
84. 3H]U46619 to washed human platelets. Prostaglandins 33 (1987) 789-797
85. 2 receptors in patients with pregnancy induced hypertension. Thromb. Res. 70 (1993) 205-210
86. 2-sensitive adenylase cyclase in human platelet membranes. Prostaglandins 27 (1984) 321-333
87. Longenecker G.L. Platelet arachidonic acid metabolism. In: Longenecker G.L. (Ed). The Platelets: Physiology and Pharmacology (1985), Academic Press, Orlando, FL 159-185
88. Maclntyre D.E. Platelet prostaglandin receptors. In: Gordon J.L. (Ed). Platelets in Biology and Pathology 2 (1981), Elsevier, Amsterdam 211-247
89. Maclntyre D.E., and Armstrong R.A. Agonists and receptors: prostaglandins and thromboxanes. In: Holmsen H. (Ed). Platelet Responses and Metabolism. Receptors and Metabolism (1987), CRC Press, Boca Raton, FL 93-103
90. Maclntyre D.E., Bushfield M., Gibson I., Hopple S., MacMillan L., McNicol A., and Rossi A.G. Human platelet receptors and receptor mechanisms for stimulatory and inhibitory lipid mediators. In: Lagarde M. (Ed). Biology of Icosanoids (1987), Colloque Inserm 321-334
91. Maclntyre D.E., and Gordon J.L. Platelets in Biology and Pathology. III. (1987), Elsevier, Amsterdam
92. Maclntyre D.E., Salzman E.W., and Gordon J.L. Prostaglandin receptors on human platelets Structure-activity relationships of stimulatory prostaglandins. Biochem. J. 174 (1978) 921-929
93. 2 receptors. J. Med. Chem. 34 (1991) 1511
94. 2 receptor antagonist to washed human platelets. J. Pharmacol. Exp. Ther. 235 (1985) 729-734
95. 2 analogs in platelets and blood vessels. Eur. J. Pharmacol. 148 (1988) 309-315
96. 2 antagonists on platelets and veins. Eur. J. Pharmacol. 111 (1985) 125-128
97. 2 antagonist to washed canine platelets. Mol. Pharmacol. 28 (1985) 163-169
98. 2 receptors in platelets and blood vessels: Evidence for different receptors. J. Pharmacol. Exp. Ther. 233 (1985) 418-424
99. 2 receptor: evidence for N-linked glycosylation. Eur. J. Pharmacol. 227 (1992) 267-274
100. Masferrar J.L., Seibert K., Zwiefel B., and Needleman P. Endogenous glucocorticoids regulate an inducible cyclooxygenase enzyme. Proc. Natl. Acad. Sci. USA 89 (1992) 3917-3921
101. 2 receptor expression in human erythroleukemia cells. Am. J. Physiol. 265 (1993) 928-934
102. 2 receptor density in rat aortas and platelets. Am. J. Physiol. 267 (1994) 887-893
103. Matsumoto T., Funk C.D., Radmark O., Hoog J.-O., Jornvall H., and Samuelsson B. Molecular cloning and amino acid sequence of human 5-lipoxygenase. Proc. Natl. Acad. Sci. 85 (1988) 26-30 3406
104. Mauco G., Dangelmaier C.A., and Smith J.B. Inositol lipids, phosphatidate and diacylglycerol share stearoylarachidonoylglycerol as a common backbone in thrombin-stimulated human platelets. Biochem. J. 224 (1984) 933-940
105. 2 receptor agonist and antagonist binding in human platelets. J. Biol. Chem. 266 (1991) 13752-13758
106. 2 for their receptor are similar in washed human platelets. Biochem. Biophys. Res. Commun. 157 (1988) 733-739
107. Meade E.A., Smith W.L., and DeWitt D.L. Differential inhibition of prostaglandin endoperoxide synthase (Cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J. Biol. Chem. 268 (1993) 6610-6614
108. 2 receptors. Eur. J. Pharmacol. 171 (1989) 179-187
109. 2 receptors in human platelets. J. Pharmacol. Exp. Ther. 210 (1979) 134-141
110. Mills D.C.B., and Macfarlane D.E. Prostaglandins and platelet adenylate cyclase. In: Silver M.J., Smith J.B., and Kocsis J.J. (Eds). Prostaglandins in Hematology (1977), Spectrum Publications Inc., New York 219-233
111. 4 hydrolase. J. Biol. Chem. 262 (1987) 13873-13876
112. Miyamoto T., Ogino N., Yamamoto S., and Hayaishi O. Purification of prostaglandin endoperoxide synthase from bovine vesicular gland microsomes. J. Biol. Chem. 251 (1976) 2629-2636
113. 2 (TP) receptors in human platelet membranes. Life Sci. 51 (1992) 431-437
114. 2 receptor. In: Samuelsson B., Paoletti R., and Ramwell P. (Eds). Advances in Prostaglandin, Thromboxane and Leukotriene Research 20 (1990), Raven Press Ltd., New York 102-109
115. 2 analogue (U46619), on human platelets. Am. J. Physiol. 253 (1987) H1035-H1043
116. 2 receptor agonist. J. Pharmacol. Exp. Ther. 251 (1989) 557-562
117. 2 with differential effects on platelets and blood vessels. Proc. Natl. Acad. Sci. USA 86 (1989) 5600-5604
118. Morton D.R., Bundy G.L., and Nishizawa E.E. Five-membered ring-modified prostacyclin analogues. In: Vane J.R., and Bergstrom S. (Eds). Prostacyclin (1979), Raven Press, New York 31-41
119. Mueller H.W., Purdon A.D., Smith J.B., and Wykle R.L. 1-O-Alkyl-linked phosphoglycerides of human platelets: Distribution of arachidonate and other acyl residues in the ether-linked and diacyl species. Lipid 18 (1983) 814-881
120. Mustard J.F., Perry D.W., Kinlough-Rathbone R.L., and Packham M.A. Factors responsible for ADP-induced release reaction of human platelets. Am. J. Physiol. 228 (1975) 1757-1765
121. Myers A., Shio H., Nicosia S., and Ramwell P. Platelet eicosanoid receptors. In: Longenecker G.L. (Ed). The Platelets: Physiology and Pharmacology (1985), Academic Press, Orlando, FL 201-220
122. 2 receptors. J. Pharmacol. Exp. Ther. 262 (1992) 632-637
123. 2 receptor antagonists: Structure-activity relationships. Adv. Prostaglandin Thromboxane Leukotriene Res. 15 (1985) 291-293
124. 2 receptor ligands, U46619 and S-145, on rabbit platelets. FEBS Lett. 234 (1988) 309-312
125. 2 receptor: cDNA, cloning, expression and Northern blot analysis. Biochem. Biophys. Res. Comm. 184 (1992) 1197-1203
126. Narumiya S., and Salmon J.A. Arachidonic acid-15-lipoxygenase from rabbit peritoneal polymorphonuclear leukocytes. Methods Enzymol. 86 (1982) 45-48
127. Narumiya S., Salmon J.A., Cottee F.H., Weatherly B.C., and Flower R.J. Arachidonic acid-15-lipoxygenase from rabbit peritoneal polymorphonuclear leukocytes. J. Biol. Chem. 256 (1981) 9583-9592
128. Needleman P., Minkes M., and Raz A. Thromboxanes: Selective biosynthesis and distinct biological properties. Science 193 (1976) 163-165
129. Needleman P., Raz A., Ferrendelli J.A., and Minkes M. Application of imidazole as a selective inhibitor of thromboxane synthase in human platelets. Proc. Natl. Acad. Sci. USA 74 (1977) 1716-1720
130. Needleman P., Raz A., Minkes M.S., Ferrendelli J.A., and Sprecher H. Triene prostaglandins: Prostacyclin and thromboxane biosynthesis and unique biological properties. Proc. Natl. Acad. Sci. USA 76 (1979) 944-948
131. Nicolaou K.C., and Petasis N.A. Synthesis of eicosanoids. In: Willis A.L. (Ed). CRC Handbook of Eicosanoids: Prostaglandins and Related Lipids (1987), CRC Press, Boca Raton, FL 1-18
132. 2: A selective inhibitor of coronary artery constriction, platelet aggregation and thromboxane production. Proc. Natl. Acad. Sci. USA 76 (1979) 2566-2570
133. Nugteren D.H. Arachidonate lipoxygenase in blood platelets. Biochim. Biophys. Acta 380 (1975) 299-307
134. Nugteren D.H. Arachidonate lipoxygenase. In: Silver M.J., Smith J.B., and Kocsis J.J. (Eds). Prostaglandins in Hematology 11 (1977), Spectrum Publications, Jamaica, N.Y. 11-25
135. Nugteren D.H. Arachidonic acid-12-lipoxygenase from bovine platelets. Methods Enzymol. 86 (1982) 49-54
136. Nugteren D.H., Buytenhek M., Christ-Hazelhof E., Moonen P., and van der Ouderaa F.J. Enzymes involved in the conversion of endoperoxides. Prog. Lipid Res. 20 (1981) 169-172
137. O'Sullivan G.M., Chilton F.H., Huggins Jr. E.M., and McCall C.E. Lipopolysaccharide priming of alveolar macrophages for enhanced synthesis of prostanoids involves induction of a novel prostaglandin H synthase. J. Biol. Chem. 267 (1992) 14547-14550
138. O'Sullivan G.M., Huggins E.M., Meade M.A., DeWitt D.L., and McCall C.E. Lipopolysaccharide induces prostaglandin H synthase-2 in alveolar macrophages. Biochem. Biophys. Res. Commun. 187 (1992) 1123-1127
139. Ogletree M.L., Harris D.N., Greenberg R., Haslanger M.F., and Nakane M. Pharmacological actions of SQ29.548, a novel selective thromboxane antagonist. J. Pharmacol. 234 (1985) 435-441
140. 2 receptors. J. Pharmacol. Exp. Ther. 262 (1992) 238-245
141. 2-receptors and molecular mechanisms in platelets and vasculature: state of the art. Pharmacol. Res. Comm. 19 (1987) 735-765
142. Perret B., Chap H.J., and Douste-Blazy L. Asymmetric distribution of arachidonic acid in the plasma membrane of human platelets A determination using purified phospholipases and a rapid method for membrane isolation. Biochim. Biophys. Acta 556 (1979) 434-446
143. 1. Biochim. Biophys. Acta 856 (1986) 421-427
144. Rink T.J. Cytosolic calcium in platelet activation. Experiment 44 (1988) 97-100
145. Rink T.J., and Sage S.O. Calcium signalling in human platelets. Annu. Rev. Physiol. 52 (1990) 431-449
146. Rome L.H., and Lands W.E.M. Structural requirements for time-dependent inhibition of prostaglandin biosynthesis by anti-inflammatory drugs. Proc. Natl. Acad. Sci. 72 (1975) 4863-4865
147. Roth G.J. Platelet and arachidonate metabolism and platelet activating factor. In: Phillips D.R., and Shuman M.A. (Eds). Biochemistry of Platelets 69 (1986), Academic Press, Orlando, FL 69-113
148. Samuelsson B., Dahlen S.-E., Lindgren J.A., Rouzer C.A., and Serhan C.H. Leukotrienes and lipoxins: Structures, biosynthesis and biological effects. Science 237 (1987) 1171-1176
149. 2, receptor in human platelet membranes. J. Biol. Chem. 261 (1986) 3025-3029
150. 2. J. Biol. Chem. 254 (1979) 2914-2917
151. 2 receptors in a particulate fraction of platelets of various species. Biochem. Pharmacol. 29 (1980) 2297-2299
152. 2in vitro. Naunyn Schmiedebergs Arch. Pharmacol 316 (1981) 252-255
153. Schwartz M.B., Hawiger J., Timmons S., and Friesinger G.C. Platelet aggregates in ischemic heart disease. Thromb. Haemost. 43 (1980) 185-188
154. 2 production in patients with ischemic heart disease: Relationships to coronary pathoanatomy, risk factors, and clinical manifestations. Am. Heart J. 101 (1981) 185-194
155. q family. J. Biol. Chem. 266 (1991) 9309-9313
156. 2) binding and activation of adenylate cyclase in platelets of diabetic and control subjects. Br. J. Clin. Pharmacol. 15 (1983) 77-81
157. 2 on human platelets. Methods Enzymol. 86 (1982) 179-193
158. 2 on human platelets. Biochem. Biophys. Res. Commun. 90 (1979) 291-296
159. 3H]-prostacyclin on platelets. J. Clin. Invest. 63 (1979) 215-220
160. Siess W. Molecular mechanisms of platelet activation. Physiol. Rev. 69 (1989) 58-178
161. + exchange as a modulator of platelet activation. Trends Biochem. Sci. 13 (1988) 148-151
162. Simmons D.L., Xie W., Chipman J.G., and Evert G.E. In: Bailey J.M. (Ed). Prostaglandins, Leukotrienes and PAF (1991), Plenum Press, New York 67-68
163. Skuballa W., and Vorbrüggen H. Synthesis of iloprost (ZK 36374): A chemically stable and biologically potent prostacyclin analogue. Adv. Prostaglandin Thromboxane Leukotriene Res. 11 (1983) 299-305
164. Smith J.B. Arachidonic acid metabolism and platelet function. Advances in Eicosanoid Research (1990), MTP Press, Lancaster, England, Keith Hillier 1-15
165. Smith J.B., and Willis A.L. Aspirin selectively inhibits prostaglandin production in human platelets. Nature New Biol. 231 (1971) 235-237
166. Smith J.B., Sedar A.W., Ingerman C.M., and Silver M.J. Prostaglandin endoperoxides: platelet shape change, aggregation and the release reaction. In: Mills D.C.B., and Pareti F.I. (Eds). Platelets and Thrombosis (1977), Academic Press, New York 83-95
167. Smith W.L. The eicosanoids and their biochemical mechanism of action. Biochem. J. 259 (1989) 315-324
168. Smith W.L., and Marnett L.J. Prostaglandin endoperoxide synthase: Structure and catalysis. Biochim. Biophys. Acta 1083 (1991) 1-17
169. Smith W.L., DeWitt D.L., Shimokawa T., Kraemer S.A., and Meade E.A. Molecular basis for the inhibition of prostanoid biosynthesis by non-steroidal anti-inflammatory drugs. Stroke 21 (1990) IV24-IV28
170. 3H]iloprost binding sites on human platelet membranes. Prog. Clin. Biol. Res. 242 (1987) 25-34
171. Tai H., Lee N., and Tai C. Inhibition of thromboxane synthesis and platelet aggregation by pyridine and its derivatives. Adv. Prostaglandin Thromboxane Leukotriene Res. 6 (1980) 447-452
172. 2 receptor of human platelet membranes. Eur. J. Pharmacol. 226 (1992) 149-156
173. 3H]BAY U 3405 to washed human platelets and platelet membranes. Biochem. Pharmacol. 44 (1992) 495-503
174. Tsai A.-L., and Wu K.K. Structure-activity relationships between prostacyclin and its platelet receptor. Eicosanoids 2 (1989) 131-143
175. Tsai A.-L., Vijjeswarapu H., and Wu K.K. Interaction between platelet receptor and iloprost isomers. Biochim. Biophys. Acta 942 (1988) 220-226
176. Tsai A.L., Kulmacz R.J., Wang J.-S., Wang Y., Van Wart H.E., and Palmer G. Heme co-ordination of Prostaglandin H Synthase. J. Biol. Chem. 268 (1993) 8554-8563
177. 2 (TP-) receptors: Evidence from antagonist but not agonist potency measurements. Br. J. Pharmacol. 102 (1991) 607-614
178. Ullrich V., and Graf H. Prostacyclin and thromboxane synthase as P-450 enzymes. Trends Pharmacol. Sci. 5 (1984) 353-355
179. 2 receptor from human blood platelets. J. Biol. Chem. 264 (1989) 16496-16501
180. Van Dorp D.A., Van Evert W.C., and Van Der Wolf C. 20-Methylprostacyclin: a powerful "unnatural" platelet aggregation inhibitor. Prostaglandins 16 (1978) 953-955
181. Vanderhoek J.Y., Bryant R.W., and Bailey J.M. Inhibition of leukotriene biosynthesis by the leukocyte product 15-hydroxy-5, 8, 11, 13-eicosatetraenoic acid. J. Biol. Chem. 255 (1980) 10064-10066
182. Vanderhoek J.Y., Bryant R.W., and Bailey J.M. 15-Hydroxy-5, 8, 11, 13-eicosatetraenoic acid: A potent and selective inhibitor of platelet lipoxygenase. J. Biol. Chem. 255 (1980) 5996-5998
183. Vanderhoek J.Y., Tare N.S., Bailey J.M., Glodstein A.L., and Pluznic D. New role for 15-hydroxy-eicosatetraenoic acid: Activator of leukotriene biosynthesis in PT18 mast/basophil cells. J. Biol. Chem. 257 (1982) 12191-12195
184. Vane J.R., and Botting R. Inflammation and the mechanism of action of anti-inflammatory drugs. FASEB J. 1 (1987) 89-96
185. 2α. Nature 244 (1973) 114-116
186. 2 on platelets. Adv. Exp. Med. Biol. 192 (1985) 109-125
187. 2 on platelet aggregation in different species. Prostaglandins 16 (1978) 373-388
188. Willis A.L. The eicosanoids: An introduction and overview. In: Willis A.L. (Ed). CRC Handbook of Eicosanoids: Prostaglandins and Related Lipids (1987), CRC Press, Boca Raton, FL 3-46
189. Xie W., Chipman J.G., Robertson D.L., Erikson R.L., and Simmons D.L. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc. Natl. Acad. Sci. 88 (1991) 2692-2696
190. Yamamoto S. Enzymes synthesizing and metabolizing prostanoids. In: Lands W.E.M. (Ed). Biochemistry of Arachidonic Acid Metabolism (1985), Martinus Nijhoff Publishing, Boston 41-50
191. Yokoyama C., Mizuno K., Mitachi H., Yoshimoto T., Yamamoto S., and Pace-Asciak C.R. Partial purification and characterization of arachidonate 12-lipoxygenase from rat lung. Biochim. Biophys. Acta 750 (1983) 237-243
192. Yokoyama C., Sinjo F., Yoshimoto T., Yamamoto S., Oates J.A., and Brash A.R. Arachidonate 12-lipoxygenase purified from porcine leukocytes by immunoaffinity chromatography and its reactivity with hydroperoxyeicosatetraenoic acids. J. Biol. Chem. 261 (1986) 16714-16721
193. Zucker M.B., and Nachmias V.T. Platelet activation. Arteriosclerosis 5 (1985) 2-18